TICKERNOMICS Sign up
Last Update: 2024-03-28 02:15:00
Lantern Pharma Inc. ( LTRN ) https://www.lanternpharma.com
10.03USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
31.15%
LTRN
119.96%
SPY
32.74%
-46.39%
LTRN
SPY
92.93%
LTRN
0.00%
SPY
224.41%
LTRN
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
106.35
87.23
0.35
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-7.44
0.00
2.60
-39.44
0.00
-5.28
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
0.00
0.00
0.00
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
4.27
-43.19
-29.06
0.00
Other Earnings and Cash Flow Stats:
Lantern Pharma Inc. ( LTRN ) Net Income TTM ($MM) is -11.93
Lantern Pharma Inc. ( LTRN ) Operating Income TTM ($MM) is -13.78
Lantern Pharma Inc. ( LTRN ) Owners' Earnings Annual ($MM) is 0.00
Lantern Pharma Inc. ( LTRN ) Current Price to Owners' Earnings ratio is 0.00
Lantern Pharma Inc. ( LTRN ) EBITDA TTM ($MM) is -13.77
Lantern Pharma Inc. ( LTRN ) EBITDA Margin is 0.00%
Capital Allocation:
Lantern Pharma Inc. ( LTRN ) has paid 0.00 dividends per share and bought back 0.129387 million shares in the past 12 months
Lantern Pharma Inc. ( LTRN ) has increased its debt by 0.06598 million USD in the last 12 months
Capital Structure:
Lantern Pharma Inc. ( LTRN ) Interest-bearing Debt ($MM) as of last quarter is 0
Lantern Pharma Inc. ( LTRN ) Annual Working Capital Investments ($MM) are 2
Lantern Pharma Inc. ( LTRN ) Book Value ($MM) as of last quarter is 40
Lantern Pharma Inc. ( LTRN ) Debt/Capital as of last quarter is 0%
Other Balance Sheet Stats:
Lantern Pharma Inc. ( LTRN ) has 21 million in cash on hand as of last quarter
Lantern Pharma Inc. ( LTRN ) has 2 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Lantern Pharma Inc. ( LTRN ) has 10 common shares outstanding as of last quarter
Lantern Pharma Inc. ( LTRN ) has 0 million USD of preferred stock value
Academic Scores:
Lantern Pharma Inc. ( LTRN ) Altman Z-Score is 21.39 as of last quarter
Lantern Pharma Inc. ( LTRN ) Piotroski Score is 1.00 as of last quarter
Corporate Governance:
Lantern Pharma Inc. ( LTRN ) largest shareholder is owning shares at 0.00 ($MM) value
Aaron G.L. Fletcher(an insider) Sold 74297 shares of Lantern Pharma Inc. ( LTRN ) for the amount of $360340.45 on 2024-02-28
17.45% of Lantern Pharma Inc. ( LTRN ) is held by insiders, and 23.66% is held by institutions
Lantern Pharma Inc. ( LTRN ) went public on 2020-06-11
Other Lantern Pharma Inc. ( LTRN ) financial metrics:
FCF:-14.10
Unlevered Free Cash Flow:-16.83
EPS:-1.18
Operating Margin:0.00
Gross Profit Margin:0.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-30.91
Beta:0.00
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Lantern Pharma Inc. ( LTRN ) :
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. It develops LP-100 for treatment in combination with the class of anticancer agent known as PARP inhibitors. The company also develops LP-300 as a combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; and LP-284, a novel small molecule and DNA damaging agent for the treatment of mantle cell lymphoma and double hit lymphoma. In addition, it offers LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.